The estimated Net Worth of Thomas R Lawrence is at least $946 Tisíc dollars as of 13 March 2017. Thomas Lawrence owns over 20,781 units of Cumberland Pharmaceuticals stock worth over $8,101 and over the last 15 years Thomas sold CPIX stock worth over $937,665.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Lawrence CPIX stock SEC Form 4 insiders trading
Thomas has made over 17 trades of the Cumberland Pharmaceuticals stock since 2011, according to the Form 4 filled with the SEC. Most recently Thomas sold 6,000 units of CPIX stock worth $38,400 on 7 April 2017.
The largest trade Thomas's ever made was selling 20,781 units of Cumberland Pharmaceuticals stock on 13 March 2017 worth over $129,673. On average, Thomas trades about 8,245 units every 100 days since 2010. As of 13 March 2017 Thomas still owns at least 6,000 units of Cumberland Pharmaceuticals stock.
You can see the complete history of Thomas Lawrence stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Thomas Lawrence's mailing address?
Thomas's mailing address filed with the SEC is 2525 WEST END AVE., SUITE 950, NASHVILLE, TN, 37203.
Insiders trading at Cumberland Pharmaceuticals
Over the last 15 years, insiders at Cumberland Pharmaceuticals have traded over $4,393,644 worth of Cumberland Pharmaceuticals stock and bought 265,077 units worth $1,208,228 . The most active insiders traders include Joey A Jacobs, Leo Pavliv a Thomas R Lawrence. On average, Cumberland Pharmaceuticals executives and independent directors trade stock every 29 days with the average trade being worth of $10,407. The most recent stock trade was executed by Caroline Young on 1 December 2022, trading 379 units of CPIX stock currently worth $849.
What does Cumberland Pharmaceuticals do?
cumberland pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. cumberland is dedicated to providing high quality products which address unmet medical needs.
What does Cumberland Pharmaceuticals's logo look like?
Complete history of Thomas Lawrence stock trades at Cumberland Pharmaceuticals
Cumberland Pharmaceuticals executives and stock owners
Cumberland Pharmaceuticals executives and other stock owners filed with the SEC include:
-
A. Kazimi,
Chairman of the Board, Chief Executive Officer -
A. J. Kazimi,
Founder, Chairman, Pres & CEO -
Leo Pavliv,
Executive Vice President - Operations, Chief Development Officer -
Leo B. Pavliv,
Exec. VP of Operations & Chief Devel. Officer -
Martin Cearnal,
Executive Vice President, Chief Commercial Officer, Director -
Martin E. Cearnal,
Exec. VP, Chief Commercial Officer & Director -
James Herman,
Vice President - National Accounts, Chief Compliance Officer -
James Lowrance Herman,
Sr. VP of National Accounts & Chief Compliance Officer -
Michael Bonner,
Senior Director Finance and Accounting and Chief Financial Officer -
Caroline Young,
Independent Director -
Kenneth Krogulski,
Independent Director -
James Jones,
Independent Director -
Joey Jacobs,
Independent Director -
Jonathan Griggs,
Independent Director -
Joseph Galante,
Independent Director -
Gordon Bernard,
Independent Director -
Erin Smith Gull,
Sr. Corp. Relations Associate -
Adam S. Mostafa,
Managing Director -
Cindy B. Patton,
Sr. Director of Field Marketing -
Jean W. Marstiller,
Sr. VP of Admin. Services & Corp. Sec. -
John Michael Hamm,
Director of Fin. & Accounting and CFO -
Thomas R Lawrence,
Director -
Martin S Jr Brown,
-
Chris T. Bitterman,
Vice Pres Sales & Marketing -
Rick Scott Greene,
Chief Financial Officer -
Robert Edwards,
Director -
Jean W Marstiller,
Sr. VP & Corp. Secretary -
Lawrence W Greer,
Director -
David L Lowrance,
Vice President and CFO -
Todd M. Anthony,
Vice Pres Organizational Dev -
John M. Hamm,
VP Chief Financial Officer